It would therefore seem appropriate that patients with confirmed pathogenic DNM1L variants follow a cardiac surveillance programme, as is in place for other forms of mitochondrial disease, with a view to appropriate pre-emptive treatment. This evidence concerns the gene DNM1L and mitochondrial disease.